Ovarian Cancer Therapy by VSVMP Gene Mediated by a Paclitaxel-Enhanced Nanoparticle.

Nanoparticles have great promise for gene delivery. However, the transfection efficiency of nanoparticle-based gene delivery systems is always unsatisfied to meet the requirement of effective gene therapy. Herein, we used low-dosage paclitaxel to enhance a nanoscaled gene delivery system that was self-assembled from N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammoniummethyl sulfate and monomethoxy poly(ethylene glycol)-poly(d,l-lactide) (DPP), creating a paclitaxel-encapsulated DPP (P-DPP) nanoparticle. The encapsulated low-dosage paclitaxel significantly improved the gene delivery efficiency of the DPP nanoparticles against multiple cancer cells, in some of which the transfection efficiency is as high as 92%. By the P-DPP nanoparticle, vesicular stomatitis virus matrix protein (VSVMP) that could induce cell apoptosis was delivered to treat ovarian cancer. The encapsulation of paclitaxel in DPP nanoparticles increased the expression of VSVMP, enhancing VSVMP to induce antiproliferation and apoptosis in SKOV3 ovarian cancer cells. Intraperitoneal administration of P-DPP-delivered VSVMP effectively inhibited the intraperitoneal metastasis of SKOV3 ovarian cancer, which was more efficient than DPP-delivered VSVMP. Moreover, it was found that the tumor cell apoptosis induction, tumor cell proliferation inhibition, and tumor angiogenesis suppression were involved in the anticancer mechanism of this nanocomplex. Our data suggest that the encapsulation of low-dosage paclitaxel can enhance the gene delivery efficiency of the DPP nanoparticles against multiple cancer cells and exert a synergistic anticancer effect with VSVMP gene in ovarian cancer treatment. The VSVMP gene therapy delivered by the paclitaxel-enhanced nanoparticle has potential application in ovarian cancer therapy.

[1]  Yi Yan Yang,et al.  Co-delivery of drugs and plasmid DNA for cancer therapy. , 2016, Advanced drug delivery reviews.

[2]  Yong Peng,et al.  The role of MicroRNAs in human cancer , 2016, Signal Transduction and Targeted Therapy.

[3]  Bertrand Z. Yeung,et al.  Paclitaxel tumor priming promotes delivery and transfection of intravenous lipid-siRNA in pancreatic tumors. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Xiangrui Liu,et al.  Paclitaxel improved gene transfection efficiency through cell synchronization in SW480 cells. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[5]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[6]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[7]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[8]  E. Chiocca,et al.  Oncolytic viruses targeting tumor stem cells. , 2014, Cancer research.

[9]  A. Zeng,et al.  Mammalian cell culture synchronization under physiological conditions and population dynamic simulation , 2014, Applied Microbiology and Biotechnology.

[10]  P. Leboulch.  Gene therapy: Primed for take-off , 2013, Nature.

[11]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2012 – an update , 2013, The journal of gene medicine.

[12]  S. Kaye,et al.  New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential , 2013, Clinical Cancer Research.

[13]  C. Dass,et al.  Intraperitoneal delivery of nanoparticles for cancer gene therapy. , 2013, Future oncology.

[14]  P. Chu,et al.  Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. , 2012, Biomaterials.

[15]  Xiaoli Wei,et al.  Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[16]  J. Pedraz,et al.  Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research , 2012, Clinical and Translational Oncology.

[17]  F. He,et al.  A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy , 2012, Nature Medicine.

[18]  G. Poli,et al.  Tumor suppressor genes and ROS: complex networks of interactions. , 2012, Free radical biology & medicine.

[19]  Huibi Xu,et al.  Role of cellular uptake in the reversal of multidrug resistance by PEG-b-PLA polymeric micelles. , 2011, Biomaterials.

[20]  J. Au,et al.  Paclitaxel tumor-priming enhances siRNA delivery and transfection in 3-dimensional tumor cultures. , 2011, Molecular pharmaceutics.

[21]  Kam W Leong,et al.  Simultaneous delivery of siRNA and paclitaxel via a "two-in-one" micelleplex promotes synergistic tumor suppression. , 2011, ACS nano.

[22]  Betty Y. S. Kim,et al.  Current concepts: Nanomedicine , 2010 .

[23]  P. Conte,et al.  Achievements and unmet needs in the management of advanced ovarian cancer. , 2010, Gynecologic oncology.

[24]  Ping Zhang,et al.  Combination of vesicular stomatitis virus matrix protein gene therapy with low‐dose cisplatin improves therapeutic efficacy against murine melonoma , 2010, Cancer science.

[25]  Yuquan Wei,et al.  Preparation of MPEG-PLA nanoparticle for honokiol delivery in vitro. , 2010, International journal of pharmaceutics.

[26]  Jana L Phillips,et al.  Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle , 2010, Nature Biotechnology.

[27]  W. Shi,et al.  Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer , 2009, Journal of Molecular Medicine.

[28]  Xia Zhao,et al.  A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  A. Fu,et al.  Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Yuquan Wei,et al.  Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. , 2007, Gynecologic oncology.

[31]  S. Wise.  Nanocarriers as an emerging platform for cancer therapy , 2007 .

[32]  Ho Sup Yoon,et al.  Co-delivery of drugs and DNA from cationic core–shell nanoparticles self-assembled from a biodegradable copolymer , 2006, Nature materials.

[33]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[34]  D. Lyles,et al.  Vesicular Stomatitis Viruses Expressing Wild-Type or Mutant M Proteins Activate Apoptosis through Distinct Pathways , 2005, Journal of Virology.

[35]  N. Rainov.  A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. , 2000, Human gene therapy.

[36]  R. Bronson,et al.  Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system , 1991, Journal of virology.

[37]  D. Blondel,et al.  Role of matrix protein in cytopathogenesis of vesicular stomatitis virus , 1990, Journal of virology.

[38]  R. Olshen,et al.  Intraperitoneal cisplatin with systemic thiosulfate protection. , 1982, Annals of internal medicine.

[39]  J. R. Walton,et al.  Treatment of transplanted murine tumors with an oncolytic virus and cyclophosphamide. , 1978, Cancer research.